These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22360644)

  • 41. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
    Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
    Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].
    Yi F; Gu Y; Chen S; Liu Y; Yin W; Zhang Y; Cao B
    Zhongguo Fei Ai Za Zhi; 2018 Jun; 21(6):481-492. PubMed ID: 29945708
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
    Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Chemotherapy for advanced non-small cell lung cancer.
    Herbst RS; Dang NH; Skarin AT
    Hematol Oncol Clin North Am; 1997 Jun; 11(3):473-517. PubMed ID: 9209907
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?
    Choi YW; Ahn MS; Jeong GS; Lee HW; Jeong SH; Kang SY; Park JS; Choi JH; Lee SY
    Lung Cancer; 2015 Feb; 87(2):155-61. PubMed ID: 25488862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Association Between Endothelial Progenitor Cells and Treatment Response in Non-Squamous Non-small Cell Lung Cancer Treated with Bevacizumab.
    Sudo K; Sato K; Sakamoto S; Hasegawa Y; Asano M; Okuda Y; Takeda M; Sano M; Watanabe H; Shioya T; Ito H
    Anticancer Res; 2017 Oct; 37(10):5565-5571. PubMed ID: 28982871
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Value of White Blood Cells Detected for the First Time After Adjuvant Chemotherapy in Primary Operable Non-Small Cell Lung Cancer.
    Hao L; Zhang J; Di Y; Tan Z
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818802813. PubMed ID: 30295143
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A Clinical Prognostic Score to Predict Survival of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy: A Retrospective Analysis.
    Gong J; Xu L; Li Z; Hu X; Liu J; Teng Y; Jin B; Zhao M; Shi J; Guo T; Shi X; Cheng Y; Liu Y; Qu X
    Med Sci Monit; 2018 Nov; 24():8264-8271. PubMed ID: 30446633
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.
    Shao YY; Lin ZZ; Chen TJ; Hsu C; Shen YC; Hsu CH; Cheng AL
    Oncology; 2011; 81(2):98-103. PubMed ID: 21986371
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
    Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
    Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival.
    Dudek AZ; Mahaseth H
    Cancer Invest; 2005; 23(3):193-200. PubMed ID: 15945504
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer?
    Ordu C; Selcuk NA; Erdogan E; Angin G; Gural Z; Memis H; Yencilek E; Dalsuna S; Pilanci K
    Medicine (Baltimore); 2014 Dec; 93(28):e299. PubMed ID: 25526475
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical and prognostic importance of XIAP and USP8 in advanced stages of non-small cell lung cancer.
    Baykara M; Yaman M; Buyukberber S; Tufan G; Demirci U; Benekli M; Coskun U; Ozet A; Umit Bagriacik E
    J BUON; 2013; 18(4):921-7. PubMed ID: 24344018
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
    Chang GC; Tsai CM; Chen KC; Yu CJ; Shih JY; Yang TY; Lin CP; Hsu JY; Chiu CH; Perng RP; Yang PC; Yang CH
    J Thorac Oncol; 2006 Jul; 1(6):520-5. PubMed ID: 17409911
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessment of interfering factors and clinical risk associated with discontinuation of pemetrexed maintenance therapy in advanced non-squamous non-small cell lung cancer.
    Shen L; Niu X; Jian H; Xu Y; Yu Y; Lu S
    Lung Cancer; 2017 Sep; 111():43-50. PubMed ID: 28838396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.
    Soria JC; Tan DSW; Chiari R; Wu YL; Paz-Ares L; Wolf J; Geater SL; Orlov S; Cortinovis D; Yu CJ; Hochmair M; Cortot AB; Tsai CM; Moro-Sibilot D; Campelo RG; McCulloch T; Sen P; Dugan M; Pantano S; Branle F; Massacesi C; de Castro G
    Lancet; 2017 Mar; 389(10072):917-929. PubMed ID: 28126333
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Excision-repair-cross-complement-1 protein as a prognostic factor in patients with advanced non-small cell lung cancer treated with platinum-based first-line chemotherapy.
    Vassalou H; Stathopoulos E; Fiolitaki G; Koutsopoulos A; Voutsina A; Georgoulias V; Mavroudis D
    Lung Cancer; 2013 Nov; 82(2):324-9. PubMed ID: 23993732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.